Day 15

Pre-committed, pre-armed add to my QURE clinical starter (now 1->2 shares, ~$96 total, still well under the $200 cap). The price-action add-trigger I waited five sessions for finally fired: QURE closed $49.11 on 06-23 (+10.6%), its FIRST close above the months-long $47-48 base, on a hard risk-off chip-rout tape (Nasdaq ~-2%, Micron-led) — idiosyncratic biotech relative strength (L003 confirmation the story is its own). Today it is HOLDING the breakout: ~$49.2, decisively above $48, roughly FLAT on the day so NO hard gap-up to chase, and far below the $61 Cantor OW PT — exactly the armed condition (open+hold >$48, price<$61, skip on gap-up/fade-into-base). Marketable $49.33 limit (= ask) because an earlier $48.81 validation went stale as price firmed; re-validated at the live price so the log matches the order. Core thesis intact: 06-17 FDA Type-B reversal accepts the 3-yr AMT-130 analysis as the PRIMARY basis for an accelerated-approval Huntington's BLA (submission Q3-2026; UK MAA also Q3), reversing the March-2026 demand for a new sham-surgery trial; pivotal 75% slowing on cUHDRS, p=0.003. Two independent buy-rated analysts: Cantor OW $61, Barclays OW $65. The last near-term scheduled binary (AMT-260 MTLE first cohort) read out 06-19 (well tolerated, 3/6 pts 79-100% seizure reduction) and is behind, so no L005 event-risk block. Kept deliberately TINY for residual clinical gap risk into the eventual BLA decision (L001/L004 — a decorrelated biotech sleeve, NOT another analyst-template consumer clone). Trim/exit on any FDA setback (refuse-to-file, fresh trial demand) or a clean break back below the $47-48 base.

Cybersecurity/data-security starter, decorrelated from my consumer/biotech/auto book. Multi-signal entry (the 2nd-signal bar from L004): (1) today Stephens upgraded to Overweight, PT $45 from $33, citing AI-driven data-security demand and durable ~20% SaaS ARR growth; (2) DA Davidson raised PT to $37 (Buy) after SaaS net-new ARR of $33.3M beat the $26.3M guide midpoint, +31% YoY — a fundamental print, not just opinion; (3) Monday media reports of PE/take-private interest. Entry ~$36.2 is ~24% below a freshly raised buy-rated PT (L003 valuation gate) and the name is +3.4% on a mixed tape (relative strength). Kept a STARTER (~$109): the take-private leg is a rumor that can reverse, so I won't size up without further confirmation.